SG11201809899RA - Method of treating hyperglycemia - Google Patents

Method of treating hyperglycemia

Info

Publication number
SG11201809899RA
SG11201809899RA SG11201809899RA SG11201809899RA SG11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA
Authority
SG
Singapore
Prior art keywords
yuanqu
vpm
dist
taiwan
international
Prior art date
Application number
SG11201809899RA
Inventor
Jui-Pao Hsu
Guang-Tzuu Shane
Meng-Ju Lee
Yi-Ping Liao
Yu-Yin Yeh
Original Assignee
Center Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center Laboratories Inc filed Critical Center Laboratories Inc
Publication of SG11201809899RA publication Critical patent/SG11201809899RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111 0 1101 010 11111 010 11111 0 11 011 11111 11111 0101110111111101111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\") WO 2017/198177 Al 23 November 2017 (23.11.2017) WIPO I P C T (51) International Patent Classification: Taipei City, Taiwan 115 (CN). LEE, Meng-Ju; 7F., No.3-2, A61K 31/277 (2006.01) A61K 9/20 (2006.01) Yuanqu St., Nangang Dist., Taipei City, Taiwan 115 (CN). A61K 9/08 (2006.01) A61K 9/48 (2006.01) LIAO, Yi-Ping; 7F., No.3-2, Yuanqu St., Nangang Dist., A61K 9/14 (2006.01) A61P 3/10 (2006.01) Taipei City, Taiwan 115 (CN). YEH, Yu-Yin; 7F., No.3-2, (21) International Application Number: Yuanqu St., Nangang Dist., Taipei City, Taiwan 115 (CN). PCT/CN2017/084746 (74) Agent: CHINA ZHENGHE INTELLECTUAL PROP- (22) International Filing Date: ERTY AGENCY; Unit C7, Floor 17, Block 2, Xihuan 17 May 2017 (17.05.2017) Plaza No.1, Xizhimenwai Street, Xicheng District, Beijing 100044 (CN). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/339,131 20 May 2016 (20.05.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant: CENTER LABORATORIES, INC. HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, [CN/CN]; 7F., No.3-2, Yuanqu St., Nangang Dist., Taipei KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, City, Taiwan 115 (CN). MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (72) Inventors: HSU, Jui-Pao; 7F., No.3-2, Yuanqu St., Nan- SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — gang Dist., Taipei City, Taiwan 115 (CN). SHANE, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — Guang-Tzuu; 7F., No.3-2, Yuanqu St., Nangang Dist., = (54) Title: METHOD = _ FIG 3 = = _ = \"o —I ISM = CZ 800 - — E = ii) = t 600 - 0 = U) = = 400 - = ii) 0 200 - E 1=1 Vehicle, 1111111 Vehicle, OF .x. Metformin \ ‘,, ,, k' ' , \ K‘ \ s \ TREATING HYPERGLYCEMIA db/m+, 10mUkg ,;• . 24' . /, ': 2 .., ; •<' .'.-- ;' ,.?' ,:;,, , , 7 I '= — = — Imo 10mUkg - ZS CM =I + .i. N t 7 / : 7 R-VPM, R-VPM, R-VPM, .• so :\". — 15mg/kg, 30mg/kg, 50mg/kg, r---1 + bid bid bid P<0.05 \\'' s ks ks E3 MI =I ... R-VPM, R-VPM, R-VPM, ....._ * 15mg/kg, 30mg/kg, 50mg/kg, P<0.05 r—i + ' 'N bid bid bid ',` ,:• , ,,, ,, / + + + *** i l - 7 - — _ Metformin Metformin Metformin u- C) isCI IN Day ,-1 co C :N (57) : Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or 1-1 ----- disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, IN and disorders related thereto. In particular, the present invention relates to methods of using (R) - (+) -verapamil or a pharmaceutically © acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia. ei O [Continued on next page] WO 2017/198177 Al MIDEDIMOMOIDEIRMEMOMOHHHOEBERVOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201809899RA 2016-05-20 2017-05-17 Method of treating hyperglycemia SG11201809899RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339131P 2016-05-20 2016-05-20
PCT/CN2017/084746 WO2017198177A1 (en) 2016-05-20 2017-05-17 Method of treating hyperglycemia

Publications (1)

Publication Number Publication Date
SG11201809899RA true SG11201809899RA (en) 2018-12-28

Family

ID=60326464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809899RA SG11201809899RA (en) 2016-05-20 2017-05-17 Method of treating hyperglycemia

Country Status (15)

Country Link
US (2) US9980935B2 (en)
EP (1) EP3413886A4 (en)
JP (3) JP6692903B2 (en)
KR (3) KR102200664B1 (en)
CN (2) CN108430467B (en)
AU (1) AU2017267006B2 (en)
BR (1) BR112018073688A2 (en)
CA (2) CA3003319C (en)
HK (1) HK1254471A1 (en)
IL (1) IL262994B2 (en)
MX (1) MX2018013943A (en)
RU (2) RU2020140694A (en)
SG (1) SG11201809899RA (en)
TW (1) TWI659738B (en)
WO (1) WO2017198177A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108430467B (en) * 2016-05-20 2021-06-22 晟德大药厂股份有限公司 Use of (R) - (+) -verapamil for the treatment of hyperglycemia and pharmaceutical compositions thereof
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
EP3981401A1 (en) * 2020-10-06 2022-04-13 InSphero AG Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic
CN117241798A (en) * 2021-04-29 2023-12-15 日东制药股份有限公司 Pharmaceutical compositions comprising GPR40 promoters and SGLT-2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616549D0 (en) * 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use
US20030092765A1 (en) * 2001-11-15 2003-05-15 John Kelly Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
CN102210865A (en) * 2005-06-03 2011-10-12 田边三菱制药株式会社 Concomitant pharmaceutical agents and use thereof
RU2338521C1 (en) * 2007-02-28 2008-11-20 Илья Николаевич Медведев Method of fast depression of activity tromboplastin generation at patients with metabolic syndrome
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
CN101869708A (en) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof
WO2010138535A1 (en) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
TWI410630B (en) * 2009-11-10 2013-10-01 Ct Lab Inc Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine dl receptor
CA2780938A1 (en) * 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
EP2573088A1 (en) * 2011-09-26 2013-03-27 Prous Institute for Biomedical Research, S.A. Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof
WO2015142865A2 (en) * 2014-03-17 2015-09-24 Massachusetts Institute Of Technology Metakaryocidal treatments
US9950995B2 (en) * 2014-10-29 2018-04-24 Center Laboratories, Inc. Crystal forms of verapamil hydrochloride
CN108430467B (en) * 2016-05-20 2021-06-22 晟德大药厂股份有限公司 Use of (R) - (+) -verapamil for the treatment of hyperglycemia and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AU2017267006B2 (en) 2019-07-11
HK1254471A1 (en) 2019-07-19
US10278943B2 (en) 2019-05-07
RU2018139578A (en) 2020-06-22
RU2739255C2 (en) 2020-12-22
US20180235921A1 (en) 2018-08-23
TWI659738B (en) 2019-05-21
IL262994B2 (en) 2023-07-01
CN113384571A (en) 2021-09-14
EP3413886A4 (en) 2019-09-18
WO2017198177A1 (en) 2017-11-23
IL262994B1 (en) 2023-03-01
JP2019503983A (en) 2019-02-14
CN108430467B (en) 2021-06-22
CA3003319A1 (en) 2017-11-23
JP6692903B2 (en) 2020-05-13
US9980935B2 (en) 2018-05-29
KR20210121305A (en) 2021-10-07
KR102200664B1 (en) 2021-01-08
RU2020140694A3 (en) 2021-10-08
JP7266327B2 (en) 2023-04-28
CA3003319C (en) 2021-05-25
EP3413886A1 (en) 2018-12-19
KR20210000757A (en) 2021-01-05
IL262994A (en) 2018-12-31
MX2018013943A (en) 2019-03-28
CA3114057A1 (en) 2017-11-23
US20170333382A1 (en) 2017-11-23
AU2017267006A1 (en) 2018-05-10
RU2018139578A3 (en) 2020-06-22
KR102423967B1 (en) 2022-07-21
KR20180058816A (en) 2018-06-01
JP2020100651A (en) 2020-07-02
CN108430467A (en) 2018-08-21
RU2020140694A (en) 2021-01-25
JP2022050572A (en) 2022-03-30
BR112018073688A2 (en) 2019-02-26
TW201740933A (en) 2017-12-01

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804915RA (en) Methods for treating huntington&#39;s disease
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809899RA (en) Method of treating hyperglycemia
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase